(Q57623484)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

0 references

1 reference

phase III clinical trial

1 reference

inferred from title

author

Per Soelberg Sørensen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Frauke Zipp

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

T L Vollmer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

K Selmaj

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

E Havrdova

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

J A Cohen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

N Sasson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Y Gilgun-Sherki

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

D L Arnold

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

BRAVO Study Group

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

English

0 references

publication date

18 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

261

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

773-783

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00415-014-7264-4

8 March 2020

exact match

0 references

cites work

Pathology of demyelinating diseases

1 reference

12 December 2020

Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis

1 reference

12 December 2020

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

1 reference

12 December 2020

Gray matter atrophy in multiple sclerosis: a longitudinal study

1 reference

12 December 2020

Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity

1 reference

12 December 2020

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination

1 reference

12 December 2020

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

1 reference

12 December 2020

Emerging oral therapies for multiple sclerosis

1 reference

12 December 2020

The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Insight into the mechanism of laquinimod action

1 reference

12 December 2020

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis

1 reference

12 December 2020

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

12 December 2020

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

1 reference

12 December 2020

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

1 reference

12 December 2020

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis

1 reference

12 December 2020

Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

1 reference

12 December 2020

The mechanism of action of interferon-β in relapsing multiple sclerosis

1 reference

12 December 2020

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

12 December 2020

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1 reference

12 December 2020

Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod

1 reference

12 December 2020

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

1 reference

12 December 2020

Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.

1 reference

12 December 2020

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

12 December 2020

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects

1 reference

12 December 2020

Placebo-controlled trial of oral laquinimod for multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

10.1007/S00415-014-7264-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24535134%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference